Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health has secured a six-month extension to its contract with Johnson & Johnson Health Care Systems to mid-2026, maintaining existing economic terms to provide its Trellus Elevate platform to IBD patients prescribed J&J therapies. The extension follows strong engagement and satisfaction metrics and broader patient access routes, underscoring growing pharmaceutical confidence in Trellus’s digital support model.
Alongside this, Trellus is rolling out its TrialSet offering with CROs ICON and PSI across multiple mid- and late-stage immunology and inflammation trials sponsored by Takeda and Sanofi, expanding its role across the clinical-to-commercial lifecycle. Despite modest 2025 revenues and ongoing funding needs, including a recently approved £5m convertible facility, the board believes contract wins and CRO deployments are improving recurring revenue visibility and strengthening its pharma-focused go-to-market strategy through 2026.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that delivers Trellus Elevate, a digital, resilience-based platform that combines data analytics, personalised programmes and expert support to manage complex chronic conditions. The company initially focuses on costly gastrointestinal diseases such as inflammatory bowel disease, and also offers TrialSet, a solution for pharmaceutical partners from clinical trials through to commercial deployment.
Average Trading Volume: 2,742,561
Technical Sentiment Signal: Sell
Current Market Cap: £1.02M
For an in-depth examination of TRLS stock, go to TipRanks’ Overview page.